CPIC 2026 | "Lu Lu" Debuts: The Spirit of the Eastern Unicorn, Empowering Innovation
Injected a unique Eastern cultural blessing into CPIC 2026
Time：
2026-06-19 18:27
Author：
xieyijun
AI pharmaceuticals, ready to tackle tough challenges
Time：
2026-06-19 18:17
Author：
xieyijun
CPIC 2026 | Heavy Guest Confirmation! Speech by Dr. Kendra Rose, Bayer BD SVP, at the conference
Operated a major ophthalmic acquisition worth $2.45 billion
Time：
2026-06-19 11:54
Author：
xieyijun
Questionnaire Gift | CPIC 2026 invites you to speak up and bring 'Lu Lu' home!
Each person is limited to one copy, the quantity is limited, first come first served!
Time：
2026-06-19 10:48
Author：
xieyijun
In 2026, the IPO of biopharmaceuticals in the US stock market is heating up again!
What are changing behind the craze?
Time：
2026-06-19 10:38
Author：
xieyijun
Johnson&Johnson's 500 'small targets' are approaching
Talvey Impact Frontline Treatment
Time：
2026-06-17 08:30
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务